Products
Abstral®
Product Information
Abstral™ provides fast and effective treatment of breakthrough pain in cancer patients. Abstral™ combines quick-dissolving sublingual tablet technology and the analgesic, fentanyl. Description
Sublingual tablet with fast onset of action for the treatment of breakthrough pain in cancer patients. Active Substance
Fentanyl Strengths
100, 200, 400 μg Indication
Breakthrough cancer pain. Regulatory Status
EMA approved June 2008. FDA approved January 2011. Inserts Code #783939. Revision Date: March 2010. Currently under registration in the AfMET region. 
Clasteon™
Product Information
Clasteon™ is used in the management of osteolysis resulting from bone metastases of malignant tumors and for the management of hypercalcemia and bone pain of malignancy. Description
A bisphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. Active Substance
Disodium clodronate Strengths
400mg, 800mg Indication
Bone metastasis reduction Regulatory Status
Approved in Canada, UK and Italy, Last revised: Sep 2009 Currently under registration in the AfMET region. 
Sancuso™
Product Information
Sancuso® (Granisetron Transdermal System) is the first and only FDA-approved patch for theprevention of Chemotherapy Induced Nausea and Vomiting (CINV) Description
Sancuso™ is a skin patch that slowly releases the medicine contained in the adhesive (glue), through clean and intact skin areas into the bloodstream while wearing the patch. Active Substance
Granisetron Strengths
34.3mg (3.1mg/24 hours) Indication
A serotonin subtype 3 (5-HT3) receptor antagonist indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days Regulatory Status
Approved by United States Food and Drug Administration (FDA) in September 2008., Inserts Code #3001566., Revision date 08/08. Currently under registration in the AfMET region. 
|